Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative.
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.
In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
Christophe Quéva, CEO of Egle Therapeutics
About Egle Therapeutics
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
For more information www.egle-tx.com
About France 2030
✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.
✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).
✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.
✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.
For more information: france2030.gouv.fr | @SGPI_avenir
About the Call for Projects “Innovations in Biotherapies and Bioproduction”
The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.
About Bpifrance
Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.
Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.
For more information: www.bpifrance.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Osmose Acquires Centillion Solutions, Inc. to Expand Its Technical Services Capabilities28.10.2025 15:00:00 CET | Press release
Osmose Utilities, Inc. today announced that it has acquired Centillion Solutions, Inc., a leading engineering services company for the telecommunications industry. Centillion provides fiber optic engineering, design, drafting and geospatial services for Fiber-to-the X (FTTx) and Hybrid Fiber Coax Networks. Founded in 2007, the company has offices in the U.S., Netherlands, UK, Australia, as well as a global design and engineering operation center in India. The acquisition of Centillion Solutions will further position Osmose with the ability to serve as a single vendor of technical services for telecom companies, providing comprehensive turn-key solutions that include pre-design walkout, Outside Plant (OSP) design, make-ready and permitting, and post construction services. “The addition of Centillion expands Osmose’s ability to deliver a complete, end-to-end fiber engineering solution providing customers with one trusted partner for planning, design, and delivery at scale,” said Mike Ada
Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies28.10.2025 14:16:00 CET | Press release
Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies Aims to improve researcher access to disease-relevant cell models Strengthens Merck’s leadership in next-generation biology Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028493228/en/ Merck and Promega will co-develop novel technologies that advance drug discovery. The agreement unites Merck’s strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies. Together, the companies aim to develop assays capable of tracking cellular activity in real time using an innovative reporter system within three-dimensional (3D)
Guidewire Signs Definitive Agreement to Acquire ProNavigator28.10.2025 14:00:00 CET | Press release
AI-powered knowledge management platform puts expertise at the fingertips of every insurance professional CONNECTIONS CONFERENCE--Guidewire (NYSE: GWRE) today announced that it has entered into a definitive agreement to acquire ProNav Technologies Ltd. (d/b/a ProNavigator), a knowledge management platform purpose-built for the P&C insurance industry. ProNavigator delivers precise, context-aware best practice information directly within insurance workflows, helping professionals work faster and more effectively. Its platform captures, connects, and surfaces institutional knowledge across claims, underwriting, and distribution. Used by 34 insurance organizations, including 12 shared customers with Guidewire, ProNavigator helps increase productivity, reduce claim cycle times, personalize customer service, and accelerate employee onboarding. Once the acquisition is complete, Guidewire will integrate ProNavigator’s insurance-trained intelligence across its platform, delivering advanced sear
Rimini Street Introduces Agentic AI ERP in Groundbreaking White Paper28.10.2025 14:00:00 CET | Press release
Rimini Street declares ERP Software dead and unveils Agentic AI ERP, a next generation, transformative ERP technology that delivers innovation faster, better and cheaper with more agility, deployed over existing ERP Software with no required, costly ERP upgrades Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the publication of its latest thought leadership white paper, The Rise of Agentic AI ERP. This landmark document presents a vision and roadmap for the next-generation technology and tools that will eventually replace today’s ERP Software which has become too big, complex, inflexible and expensive to meet the needs of a fast-changing world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028696910/en/ Rimini Street In
Gurobi Appoints Dr. Oliver Bastert as Chief Technology Officer28.10.2025 14:00:00 CET | Press release
Dr. Bastert leads Gurobi’s R&D team, advancing innovation in the company’s optimization technology. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce the appointment of Dr. Oliver Bastert to the role of Chief Technology Officer, leading the company’s Research and Development team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028639754/en/ Dr. Oliver Bastert, CTO, Gurobi Optimization "We are thrilled to have Dr. Bastert onboard as our Chief Technology Officer,” said Duke Perrucci, CEO of Gurobi Optimization. “Oliver plays a pivotal role in advancing our solver and driving innovation. As we continue our mission to bring optimization everywhere, his leadership will be instrumental." Dr. Bastert joined the Gurobi team in February and brings over 20 years of experience in B2B software, SaaS, and AI technologies. Prior to joining Gurobi, he served as Vice President of Product Man
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom